GlassScriptPhysician profile
Hunter Douglas Smith
NPI 1811580566
$7,045.12
in general payments reported to CMS, 2019-2025
25 companies · $2,897 in 2025
The $2,897 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,346 · 2024: $2,802 · 2025: $2,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,028 · Consulting Fee: $644 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,028.06 |
| Consulting Fee | $644.00 |
| Education | $373.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,294.48 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,233.69 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $1,000.00 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $992.40 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $623.01 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $617.19 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $354.54 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $170.53 | 2024-2025 | |
| Amgen INC. | $155.18 | 2023-2025 | Otezla, Otezla |
| Ani Pharmaceuticals, INC. | $104.93 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $91.41 | 2024 | |
| Leo Pharma INC. | $81.42 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $44.21 | 2025 | Nemluvio, Aklief |
| Organon LLC | $35.51 | 2024 | |
| Sun Pharmaceutical Industries INC. | $34.33 | 2023-2025 | Blu-U |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.28 | 2025 | Spevigo |
| Sandoz INC. | $28.06 | 2023-2024 | Hyrimoz |
| Kerecis Limited | $23.08 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Convatec INC. | $22.01 | 2024 | |
| Organogenesis INC. | $21.54 | 2024 | |
| Botanix Sb INC | $19.69 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $19.12 | 2023 | Idacio |
| Novo Nordisk INC | $17.01 | 2025 | Ozempic, Rybelsus |
| Incyte Corporation | $16.08 | 2024 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $15.42 | 2024 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.